TheraRadar
← Back
Data updated: Jun 28, 2026

PRAXAIR CANADA INC

Pharma
Pharmaceuticals

PRAXAIR CANADA INC is a pharmaceutical company with 2 FDA-approved products.

2013
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

PRAXAIR CANADA INC's Key Drugs

PRAXAIR CANADA INC's core commercial portfolio centers on NITROGEN, NF, OXYGEN, USP — its most strategically important drugs approved in the last 15 years.

NITROGEN, NF
Other
Approved 2013
OXYGEN, USP
Respiratory
Approved 2013

PRAXAIR CANADA INC's Recent FDA Approvals

New NDA/BLA approvals for PRAXAIR CANADA INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PRAXAIR CANADA INC's Therapeutic Areas

Disease areas where PRAXAIR CANADA INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PRAXAIR CANADA INC Pipeline Snapshot

Active clinical trials for PRAXAIR CANADA INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NITROGEN, NF leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling